| Revision as of 11:32, 24 October 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank').← Previous edit |
Latest revision as of 08:05, 18 December 2024 edit undoCs california (talk | contribs)Extended confirmed users35,713 editsNo edit summary |
| (23 intermediate revisions by 16 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Pharmaceutical drug used to treat blood clots}} |
|
{{Drugbox |
|
{{Drugbox |
|
| verifiedrevid = 402476042 |
|
| verifiedrevid = 457131584 |
|
|
| drug_name = Anistreplase |
|
| IUPAC_name = |
|
|
⚫ |
| IUPAC_name = <!--Clinical data --> |
|
|
|
|
⚫ |
| tradename = Eminase |
| ⚫ |
<!--Clinical data--> |
|
|
⚫ |
| Drugs.com = {{drugs.com|CONS|anistreplase}} |
| ⚫ |
| tradename = Eminase |
|
|
⚫ |
| pregnancy_category = |
| ⚫ |
| Drugs.com = {{drugs.com|CONS|anistreplase}} |
|
|
⚫ |
| legal_status = |
| ⚫ |
| pregnancy_category = |
|
|
⚫ |
| routes_of_administration = <!--Pharmacokinetic data --> |
| ⚫ |
| legal_status = |
|
|
⚫ |
| bioavailability = |
| ⚫ |
| routes_of_administration = |
|
|
⚫ |
| protein_bound = |
|
|
|
|
⚫ |
| metabolism = |
|
<!--Pharmacokinetic data--> |
|
| ⚫ |
| bioavailability = |
|
| ⚫ |
| protein_bound = |
|
| ⚫ |
| metabolism = |
|
|
| elimination_half-life = 90 minutes |
|
| elimination_half-life = 90 minutes |
|
|
<!--Identifiers -->| CAS_number_Ref = {{cascite|correct|??}} |
|
|
|
|
⚫ |
| CAS_number = 81669-57-0 |
|
<!--Identifiers--> |
|
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
| CASNo_Ref = {{cascite}} |
|
|
|
| UNII = 5O8V541HJ6 |
| ⚫ |
| CAS_number = 81669-57-0 |
|
|
| ATC_prefix = B01 |
|
| ATC_prefix = B01 |
|
| ATC_suffix = AD03 |
|
| ATC_suffix = AD03 |
|
| ATC_supplemental = |
|
| ATC_supplemental = |
|
| PubChem = |
|
| PubChem = |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = DB00029 |
|
| DrugBank = DB00029 |
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| KEGG = D02947 |
|
| KEGG = D02947 |
|
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
|
|
|
<!--Chemical data--> |
|
<!--Chemical data -->| molecular_weight = approx. 131 kg/mol |
|
| molecular_weight = approx. 131,000 g/mol |
|
|
}} |
|
}} |
|
|
'''Anistreplase''' is a ] drug. It is also known as '''anisoylated plasminogen streptokinase activator complex''' (APSAC). As a thrombolytic drug, it is used to treat ] in emergency situations. |
| ⚫ |
'''Anistreplase''' is a ] drug.<ref name="pmid8563585">{{cite journal |author=Rawles J |title=Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT) |journal=BMJ |volume=312 |issue=7025 |pages=212–5 |year=1996 |month=January |pmid=8563585 |pmc=2350007 |doi= |url=http://bmj.com/cgi/pmidlookup?view=long&pmid=8563585}}</ref><ref name="pmid7612317">{{cite journal |author=Hannaford P, Vincent R, Ferry S, Hirsch S, Kay C |title=Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners |journal=Br J Gen Pract |volume=45 |issue=393 |pages=175–9 |year=1995 |month=April |pmid=7612317 |pmc=1239197 |doi= |url=}}</ref><ref name="pmid8289038">{{cite journal |author=Rawles J, Light J |title=Loss of quality adjusted days as a trial endpoint: effect of early thrombolytic treatment in suspected myocardial infarction. Grampion Region Early Anistreplase Trial (GREAT) |journal=J Epidemiol Community Health |volume=47 |issue=5 |pages=377–381 |year=1993 |month=October |pmid=8289038 |pmc=1059832 |doi= 10.1136/jech.47.5.377|url=}}</ref> |
|
|
|
|
|
|
|
== Uses == |
|
Anistreplase has been developed by ] as Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC) |
|
|
|
Anistreplase is used to treat ] in emergency situations such as ].<ref name="pmid8563585">{{cite journal|author=Rawles J|date=27 January 1996|title=Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)|url=https://www.bmj.com/content/312/7025/212.full|journal=]|volume=312|issue=7025|pages=212–5|doi=10.1136/bmj.312.7025.212|pmc=2350007|pmid=8563585}}</ref> Early treatment gives better outcomes.<ref name="pmid8563585" /> |
|
|
|
|
|
==Mechanism== |
|
== History == |
|
⚫ |
Anistreplase has been developed by ] under the brand name Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC) after its components.<ref name="pmid8563585" /><ref name="pmid7612317">{{cite journal|vauthors=Hannaford P, Vincent R, Ferry S, Hirsch S, Kay C|date=April 1995|title=Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners|journal=Br J Gen Pract|volume=45|issue=393|pages=175–9|pmc=1239197|pmid=7612317}}</ref><ref name="pmid8289038">{{cite journal|vauthors=Rawles J, Light J|date=October 1993|title=Loss of quality adjusted days as a trial endpoint: effect of early thrombolytic treatment in suspected myocardial infarction. Grampion Region Early Anistreplase Trial (GREAT)|journal=J Epidemiol Community Health|volume=47|issue=5|pages=377–381|doi=10.1136/jech.47.5.377|pmc=1059832|pmid=8289038}}</ref> |
|
It is a complex of purified human plasminogen and bacterial streptokinase that has been acylated to protect the enzyme's active site. When the drug is administered, the acyl group gets hydrolyzed, thereby freeing the activator complex. It converts ] to ], which in turn degrades fibrin (]s) to fibrin split products. |
|
|
|
|
|
|
==References== |
|
== References == |
|
{{reflist}} |
|
{{reflist}} |
|
|
|
|
| Line 45: |
Line 43: |
|
|
|
|
|
] |
|
] |
|
|
] |
|
|
|
|
|
|
|
{{blood-drug-stub}} |
|
{{blood-drug-stub}} |
|
|
|
|
] |
|
|
] |
|
